ImageneBio Q2 2026: $136.2M Cash Runway into 2028, Olevaprubart Phase 2b on Track
IMA sits 45% above its 52-week low of $3.94 on light trading volume (0.3× avg).
Summary
ImageneBio posted a $10.2M Q2 net loss but holds $136.2M in cash, funding operations into 2028. Its lead drug, olevaprubart, is advancing in a pivotal atopic dermatitis trial with data due in late 2027, and a new Phase 2 in alopecia areata is planned for 2026.
Key Events · Earnings and Guidance · IMA
-
Cash Runway Extended to Q1 2028
Ended Q2 2026 with $136.2M in cash, equivalents, and marketable securities, following a $30M PIPE in April 2026. Management expects this to fund planned operations into the first quarter of 2028, removing near-term financing overhang.
-
Q2 2026 Financial Results
Net loss of $10.2M ($0.63/share) vs. $10.7M ($4.46/share) in Q2 2025. R&D expenses rose to $6.7M from $5.7M, and G&A jumped to $5.1M from $1.7M, reflecting increased clinical trial and personnel costs.
-
Olevaprubart Phase 2b ADAPTIVE Trial Progressing
The amended protocol is implemented, and the IDMC recommended the study proceed without changes on July 23, 2026. Topline data is anticipated in Q4 2027. A long-term extension study is now enrolling patients who completed one year in ADAPTIVE.
-
New Phase 2 Trial in Alopecia Areata Planned
ImageneBio remains on track to initiate a Phase 2 study of olevaprubart in alopecia areata in 2026, with initial data expected in 2028, leveraging existing clinical infrastructure.
Analysis · IMA · Life Sciences
ImageneBio's Q2 2026 results show a net loss of $10.2 million, but the real story is the strengthened balance sheet — $136.2 million in cash and securities, enough to fund operations into early 2028. That removes near-term dilution risk and gives the company a clear path to key clinical readouts. The Phase 2b ADAPTIVE trial in atopic dermatitis is progressing under an amended protocol, with topline data expected in Q4 2027, and a Phase 2 trial in alopecia areata is set to start this year. An independent data monitoring committee gave the ADAPTIVE study a clean bill of health in July, and no safety red flags have emerged. The cash cushion and advancing pipeline shift the narrative from survival to execution.
At the time of this filing, IMA was trading at $5.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.4M. The 52-week trading range was $3.94 to $17.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.